Dr. Azzam A Maghazachi received a master degree from New York University Medical School (USA), and a PhD degree in Immunology from the University of Manitoba Medical School (Canada). He did post-doctoral fellowships at NYU Medical School (USA) and at the Pittsburgh Cancer Institute. Between 1988-2005, he held several senior positions in various institutes and universities in the USA, Canada and Norway. Between 2004-2007 he was the Chief Scientific Officer at Bio-Quant, Inc. in San Diego, and between 2007-2015 was a Professor of Physiology in the faculty of Medicine at the University of Oslo, Norway, and he is currently a professor of Immunology in the college of Medicine, University of Sharjah.He and his group were the first to identify all chemokine receptors on NK cells and were the first to examine the biological activities of chemokines on these cells. Later, they identified lysophospholipids and oxidized lipids receptors on NK cells and investigated the effects of these lipids. They also discovered a new subset of NK cells that secrete both IL-17 and IFN-g, and designated them as NK17/NK1 cells. Dr. Maghazachi is an expert in cancer immunotherapy field and has developed clinical trials using natural killer cells to treat various cancers.His research interests are cancer immunology, autoimmune diseases, chemokines, and drug mechanisms of action. Dr. Maghazachi is an editor or editor-in-chief on more than 10 scientific journals in the fields of Immunology, Oncology and Neuroscience. He published more than 100 scientific papers as well as book chapters and ebooks.